ArticleClinical and experimental hepatology2024
Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease.
Article in Clinical and experimental hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unmet needs of metabolic dysfunction - Associated "fatty or steatotic" liver disease.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: Metabolic associated steatotic liver disease (MASLD) was proposed to replace non-alcoholic fatty liver disease (NAFLD) in 2023. It has different diagnostic criteria from metabolic associated fatty liver disease (MAFLD). The comparison between the two disease names and diagnostic criteria deserves investigation. Material and methods: We recruited participants from the Taiwan Bio-bank database. NAFLD was diagnosed based on the presence of hepatic steatosis after excluding chronic hepatitis B or C virus infection, chronic drinkers, or other known liver diseases. According to the presence of cardiometabolic criteria, NAFLD is divided into two groups: MASLD and cryptogenic steatotic liver disease (SLD). The "missing" group was defined as those patients who met the diagnostic criteria for MASLD but not for MAFLD. Cryptogenic SLD was used as the control group. We used the NAFLD fibrosis score (NFS) as an indicator for liver fibrosis. Results: This study included 17,595 participants, among whom 7,274 (41.3%) had MASLD, and 6,905 had pure MAFLD, defined as MAFLD having no other causes of liver diseases. The cryptogenic SLD group consisted of 264 (1.5%) patients, while the "missing" group had 369 patients. There were no differences in metabolic parameters, liver markers and the percentage of carotid plaques between these two groups. When comparing the "missing" group to the control group, the "missing" group had higher NFS and a higher proportion of carotid plaques. Conclusions: In this large, population-based study, is not advisable to exclude the "missing" group having higher risk of liver fibrosis and atherosclerosis than controls. MASLD misses fewer high-risk patients than pure MAFLD for replacing NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.